Why the study?
Does enteric-coated low-dose ASA reduce the antiplatelet effect compared to plain ASA in patients requiring antithrombotic prophylaxis?
Does enteric-coated low-dose ASA reduce the antiplatelet effect compared to plain ASA in patients requiring antithrombotic prophylaxis?
Enteric-coated low-dose aspirin may have reduced bioavailability and antiplatelet efficacy compared to plain aspirin, potentially compromising cardiovascular prophylaxis.
May favor plain over enteric-coated ASA for reliable antiplatelet effect; leaves open impact on clinical outcomes.
Low-dose acetylsalicylic acid (ASA) is widely used as antithrombotic prophylaxis. Enteric-coated ASA has been developed to decrease the risk of gastrointestinal side effects. The consequences of enteric coating on pharmacokinetics and antiplatelet effect of ASA have not systematically been assessed. This MiniReview demonstrates that data from clinical trials indicate that enteric coating can reduce the antiplatelet effect of ASA compared to plain ASA. This is possibly due to decreased bioavailability of ASA caused by prolonged solvation and absorption of the enteric-coated formulations. Therefore, low-dose enteric-coated ASA might not be bioequivalent to plain ASA, entailing the risk of insufficient cardiovascular prophylaxis.
No takes yet. Share an insight, caveat, or question.
Haastrup et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: